Inicio › Cáncer de seno › Misuri
Ensayos clínicos de Cáncer de seno en Misuri
75 estudios sobre Cáncer de seno buscan participantes en Misuri.
Ciudades en Misuri
- St. Louis64 estudios
- Kansas City34 estudios
- Springfield10 estudios
- Saint Joseph7 estudios
- Lee's Summit7 estudios
- O'Fallon6 estudios
- Columbia6 estudios
- Joplin4 estudios
- Cape Girardeau4 estudios
- Rolla3 estudios
Texto oficial del estudio (inglés)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- HCA Midwest Division, Kansas City
ReclutandoFase 3
Edades de 18 a 100 · Todos los sexos · Actualizado el 29 sept 2026 · NCT05827081An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
- Washington University in St Louis, St Louis
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07222267A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, St Louis
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06103864ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Washington University School of Medicine- Siteman Cancer Center, St Louis
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07007559A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Saint Luke's Cancer Institute ( Site 0027), Kansas City
- Washington University School of Medicine ( Site 0076), St Louis
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06312176A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Washington University, School of Medicine, St Louis
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06172478A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Saint Luke's Cancer Institute ( Site 0059), Kansas City
- Washington University Siteman Cancer Center ( Site 0031), St Louis
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06966700A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Local Institution - 0140, St Louis
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT06618287Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Kansas City
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Mercy Health - Sindelar Cancer Center, St Louis
- Mercy Health - Pratt Cancer Center, St Louis
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07214532A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Washington University School of Medicine, St Louis
ReclutandoFase 2
Edades de 18 en adelante · Mujeres · Actualizado el 22 sept 2026 · NCT07287098Cognitive Rehabilitation Following Breast Cancer Treatment
- University of Missouri, Columbia
Reclutando
Edades de 20 a 75 · Mujeres · Actualizado el 22 sept 2026 · NCT06545045A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Washington University School of Medicine in St. Louis, St Louis
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07213791A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Saint Luke's Cancer Institute, Kansas City
- Oncology Hematology Associates, Springfield
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07174336A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Washington University, St Louis
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07114601A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Washington Univ. School of Medicine, St Louis
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07109726ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Saint Luke's Hospital of Kansas City, Kansas City
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07173751A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Saint Luke's Hospital of Kansas City, Kansas City
- Washington University School of Medicine, St Louis
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT06827236Precision Supplemental Imaging in Women With Dense Breasts
- Washington University School of Medicine, St Louis
ReclutandoSe aceptan voluntarios sanos
Edades de 25 a 55 · Mujeres · Actualizado el 16 sept 2026 · NCT07277738A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Siteman Cancer Center, St Louis
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT06492616A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, St Louis
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 sept 2026 · NCT05123482A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- Washington University School of Medicine, St Louis
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 sept 2026 · NCT06440005Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- St. Lukes Hospital of Kansas City, Kansas City
- Washington University School of Medicine, St Louis
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 sept 2026 · NCT06625775A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Saint Luke's Cancer Institute, Kansas City
- Washington University School of Medicine, St Louis
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 sept 2026 · NCT06253871A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
- Washington University Medical School, St Louis
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT05307705A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Washington University Siteman Cancer Center, St Louis
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT07100106To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
- HCA Midwest Division, Kansas City
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT07368998Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Washington University School of Medicine- Siteman Cancer Center, St Louis
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT06982521Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Oncology Hematology Associates, Springfield
ReclutandoEstudio observacional
Edades de 18 a 99 · Todos los sexos · Actualizado el 3 sept 2026 · NCT07211178A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- HCA Midwest Health, Kansas City
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT06790693Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
- Washington University School of Medicine, St Louis
ReclutandoEstudio observacional
Edades de 18 a 50 · Mujeres · Actualizado el 2 sept 2026 · NCT06904365The Vanguard Study: Testing a New Way to Screen for Cancer
- Saint Luke's Hospital of Kansas City, Kansas City
- Washington University School of Medicine, St Louis
ReclutandoSe aceptan voluntarios sanos
Edades de 45 a 75 · Todos los sexos · Actualizado el 2 sept 2026 · NCT06995898Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- y 21 más
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 a 75 · Todos los sexos · Actualizado el 2 sept 2026 · NCT05334069Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- y 29 más
ReclutandoFase 3
Edades de 18 a 60 · Mujeres · Actualizado el 2 sept 2026 · NCT05879926A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Washington University, St Louis
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 ago 2026 · NCT07029399Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- WA Uni School Of Med, St Louis
ReclutandoFase 1/2
Edades de 18 a 100 · Todos los sexos · Actualizado el 27 ago 2026 · NCT06726148A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- Washington University School of Medicine - Siteman Cancer Center, St Louis
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 ago 2026 · NCT07383506A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Washington University, Siteman Cancer Center, St Louis
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 ago 2026 · NCT06774963Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
- Universtiy Health, Kansas City
- KCCC South, Kansas City
- Research Medical Center, Kansas City
- y 2 más
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Todas las edades · Todos los sexos · Actualizado el 18 ago 2026 · NCT02302742Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- University of Kansas Cancer Center - North, Kansas City
- y 6 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT06500481De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.